Pat Garcia-Gonzalez Receives Outstanding Contribution to Cancer Control Award by UICC

The Max Foundation CEO recognized for unwavering dedication to global, widespread health equity

Pat Garcia-Gonzalez joins shortlist of nominees for UICC’s Outstanding Contribution to Cancer Control Award

Pat joins Paul Farmer, President Joe Biden, and other world leaders in "Driving innovation to advance cancer control equitably"

Novartis, The Max Foundation, and a young girl who dreamed to be a lawyer

The Max Foundation and Novartis renew their commitment to CML patients

Welcoming two new members to our Strategic Innovation Advisory Board

Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD join the board this March

The Max Foundation Welcomes Bryan Murphy-Eustis as Vice President of Programs

We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs. Bryan joins the team with more than 18...

Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a...

The Max Foundation’s 2019 Annual Report is Now Live

“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.

The Max Foundation expands collaboration with Pfizer

The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer's innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.

The Max Foundation’s access program exceeds 10 million daily doses of cancer treatment distributed to patients worldwide

Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.

The Max Foundation and Cepheid expand collaboration to increase access to diagnostics

The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).

Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian

Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.

Welcoming our New Vice President of Development

The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.